As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.
Image de cellules par imagerie issue de l'étude de la combinaison de 2 médicaments pour le traitement de la mucoviscidose et des myopathies Image de cellules par imagerie issue de l'étude de la combinaison de 2 médicaments pour le traitement de la mucoviscidose et des myopathies

Xavier Nissan’s muscular dystrophies pharmacology team at I-Stem, in partnership with Isabelle Richard from Généthon and the company Kantify, has identified a pharmacological combination conferring a novel mode of action potentially efficacious against not only limb-girdle muscular dystrophy types R3s and R5 but also cystic fibrosis. The discovery was made possible by marrying competencies and knowledge in cellular models for disease, high throughput drug screening, myopathy mechanisms and artificial intelligence.

Limb-girdle muscular dystrophy (LGMD) type R3, like the 30 some-odd other types of the disease, presents as progressive weakening of mostly the hip and shoulder muscles. This particular type is caused by mutations in alpha-sarcoglycan, a protein within the dystrophin glycoprotein complex, itself an element within the membrane of striated muscle that protects this latter from contraction-induced damage. The mutation most frequently associated with the disease, called R77C, involves an amino acid substitution resulting in abnormal folding of α-sarcoglycan. Once identified by a cellular quality control mechanism, the misfolded protein is broken down by proteasomes, one of the cell’s many organelles.

Researchers from two of Genopole’s laboratories, I-Stem and Genethon (AFM-Téléthon, Inserm, University of Evry Paris-Saclay) teamed to identify drugs capable of inhibiting that breakdown, because even misfolded, α-sarcoglycan does remain partially functional. They thus developed a cellular model of the disease from patient fibroblasts and thereafter tested 958 drugs already approved by the American Food and Drug Administration for other indications. This exploration of drugs approved for other uses, called drug repositioning, offers many advantages, including the possibility of getting treatments to patients faster. The pharmaceutical compounds were tested alone or in combination with a low dose of bortezomib, a molecule known to inhibit the proteasome but also associated with cytotoxic effects at efficacious doses. Thus, the objective of the team’s approach was to confer protection for the muted α-sarcoglycan while minimizing the cytotoxic effects of bortezomib. In the study, the researchers performed an ADMET (absorption, distribution, metabolism, elimination and toxicity) analysis via an artificial intelligence developed by Kantify and trained for assay results prediction on 150,000 compounds. That AI analysis considered 76 ADMET endpoints and ranked the retained molecules in terms of benefit-risk, thus indicating their potential for successful clinical development.

The work by the Évry team led to the identification of 47 possibly-therapeutic compounds. Among them, givinostat in particular showed a strong ability to restore the expression of mutant cell-membrane α-sarcoglycan. Indeed, givinotat is currently in phase III trials for Duchenne muscular dystrophy and showing promising preliminary results. Givinostat appears to inhibit the cell’s autophagic pathway, a system complementary to the proteasome for ensuring the elimination of abnormal proteins.

Thus, beyond the identification of givinostat + bortezomib as a promising combination against LGMD type R3, the I-Stem/Genethon study published in Frontiers in Pharmacology on 27 April 2022, also shed light on the double, autophagic and proteasomic, mechanism involved in the degradation of the misfolded protein. That discovery led the team to extend its study to two diseases with similar protein-breakdown aspects: LGMD type R5 and cystic fibrosis, on which the givinostat + bortezomib combination also showed positive effects.

Toward new treatments for rare genetic diseases?

Such approaches, wherein rare genetic diseases (most of which remain incurable) are considered in terms of groups of diseases sharing molecular mechanisms, is revolutionizing drug discovery.

Study schema ⬇️

Schéma de synthèse de l’étude de la combinaison de médicaments pour le traitement des myopathies et de la mucoviscidose
The screening of 958 compounds on a cellular model of limb-girdle muscular dystrophy type R3 (LGMDR3) and an ADMET artificial intelligence analysis identified givinostat as the primary compound of interest, studied thereafter for its mode of action. The combination of givinostat and bortezomib was shown to have potential therapeutic effect not only for LGMDR3, but also for LGMDR5 and cystic fibrosis.


This study by the I-Stem/Genethon team illustrates the potential of Genopole’s actors for the development of innovative therapies.


Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination.

Frontiers in Pharmacology, 2022

Press Release

Article posted on 18 May 2022


Latest news

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

CNRGH - Consequences of phthalate exposure during pregnancy

Consequences of phthalate exposure during pregnancy

Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.

INtegrare / Généthon - Efficacité à long terme de la thérapie génique d’un déficit immunitaire

Long-term efficacy for an immunodeficiency gene therapy

A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.

I-Stem, IPSEN & LMN recreate the human muscle-nerve system

A cellular model to recreate the human muscle-nerve system

Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.

Genoscope - CNS - Genopole's laboratory

Filling the gaps in the banana’s genome

Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.

traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.


Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

View all >
With the support from
Région île de France